GENDER-BASED ANALYSIS OF ADVERSE EFFECTS OF DAPAGLIFLOZIN AND EMPAGLIFLOZIN IN CHRONIC KIDNEY DISEASE ASSOCIATED WITH TYPE 2 DIABETES: A COMPARATIVE

Study of Emerging Research Directions

Author: **Abdiqodirova D.A.**

Tashkent Medical Academy, Tashkent, Uzbekistan

Introduction

Type 2 diabetes mellitus (T2DM) remains a significant global health issue and a leading cause of chronic kidney disease (CKD). Sodium-glucose cotransporter-2 (SGLT2) inhibitors, including dapagliflozin and empagliflozin, have demonstrated protective effects on renal function. However, their adverse effects may differ based on patient characteristics, particularly gender. This study explores emerging research on gender disparities in the adverse effects of dapagliflozin and empagliflozin among patients with CKD and T2DM.

Understanding the impact of dapagliflozin and empagliflozin on male and female patients with CKD is crucial for optimizing treatment strategies. While both drugs have demonstrated significant benefits in renal protection and cardiovascular risk reduction, concerns regarding gender-specific adverse reactions, including urinary tract infections, ketoacidosis, and volume depletion, remain under investigation.

This study aims to provide a comparative analysis of the adverse effects of dapagliflozin and empagliflozin in male and female patients with CKD associated with T2DM. By reviewing clinical outcomes and recent research directions, we seek

to highlight gender-based variations and their implications for personalized treatment approaches.

Key words

•Type 2 Diabetes Mellitus (T2DM), Chronic Kidney Disease (CKD), Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Dapagliflozin, Empagliflozin, Gender Differences, Adverse Effects, Urinary Tract Infections (UTIs), Diabetic Ketoacidosis (DKA), Pharmacokinetics, Personalized Medicine.

Study Rationale

While the efficacy of SGLT2 inhibitors in CKD management is well-established, there is limited research on how gender influences their side effect profiles. Variations in hormonal regulation, renal physiology, and drug metabolism between men and women may contribute to differences in adverse event occurrences. A deeper understanding of these differences can help refine treatment strategies and enhance patient safety.

Objective

This study aims to compare the frequency and severity of adverse reactions to dapagliflozin and empagliflozin in male and female CKD patients with T2DM. It also seeks to identify underlying physiological and genetic factors that may influence these gender-specific differences.

Methodology

Systematic review of clinical trials and observational studies reporting gender-related adverse effects of SGLT2 inhibitors.

Analysis of pharmacokinetic data to assess drug metabolism differences between males and females.

Meta-analysis of common adverse effects, including urinary tract infections (UTIs), diabetic ketoacidosis (DKA), dehydration, hypotension, and electrolyte imbalances.

Investigation of genetic polymorphisms and hormonal influences on drug response.

Mechanisms of SGLT2 Inhibitors and Their Gender-Specific Implications

Glucosuria and UTI Risk: Due to anatomical differences and vaginal microbiota composition, women are more susceptible to glucosuria-associated UTIs.

Blood Pressure Regulation: Variations in the renin-angiotensin-aldosterone system (RAAS) between genders may impact the hypotensive effects of SGLT2 inhibitors.

Ketogenesis and Metabolism: Women might be more predisposed to DKA due to differences in insulin sensitivity and lipid metabolism.

Electrolyte Imbalances: Sex hormones influence sodium and potassium handling in the kidneys, contributing to different risks of electrolyte disturbances.

Comparative Analysis of Adverse Effects in Men and Women

A comparative evaluation of gender differences in the adverse effects of dapagliflozin and empagliflozin, focusing on variations in incidence rates, severity, and clinical outcomes.

Emerging Research Directions

Hormonal Influence on Drug Metabolism: Investigating how estrogen and testosterone impact the pharmacokinetics of SGLT2 inhibitors.

Microbiome and Infection Risk: Exploring gender-based differences in gut and urogenital microbiota and their impact on infection risks.

Genetic Variability in Drug Response: Identifying genetic polymorphisms that influence gender-related side effects.

Long-Term Cardiovascular and Renal Outcomes by Gender: Examining whether gender disparities in adverse effects affect long-term disease progression.

Personalized Medicine Approaches: Developing gender-specific treatment protocols to optimize efficacy and minimize adverse effects.

Discussion

Gender-based variations in the adverse effects of SGLT2 inhibitors underscore the need for personalized treatment strategies. Women appear to have a higher risk of UTIs and DKA, whereas men may experience greater hemodynamic instability. These differences suggest that individualized monitoring and dose adjustments could enhance safety and treatment effectiveness.

Conclusion and Recommendations

1. Women prescribed dapagliflozin or empagliflozin should be closely monitored for UTIs and fungal infections, with potential prophylactic interventions.
2. Men with cardiovascular conditions should be evaluated for hypotension and dehydration risks before initiating therapy.
3. Further pharmacokinetic studies should be conducted to determine optimal dosing strategies for each gender.
4. Genetic screening for variations in drug metabolism may help identify patients at higher risk of adverse effects.

5. Integrating personalized medicine approaches into clinical practice could improve treatment outcomes and patient safety.

References.

1. Jabbour, S., Seufert, J., Scheen, A. J., Bailey, C. J., Karup, C., & Meininger, G. (2018). Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from clinical trials. Diabetes Therapy, 9(4), 1455-1469.

2. Heerspink, H. J. L., Stefansson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F. F., & Wheeler, D. C. (2020). Dapagliflozin in patients with chronic kidney disease. New England Journal of Medicine, 383(15), 1436-1446.

3. Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., & Leiter, L. A. (2019). Dapagliflozin and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 380(4), 347-357.

4. Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., & Mahaffey, K. W. (2019). Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. New England Journal of Medicine, 380(24), 229-2306.

5. Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., & Johansen, O. E. (2015). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New England Journal of Medicine, 373(22), 2117-2128.

6. Inzucchi, S. E., Zinman, B., Fitchett, D., Wanner, C., Ferrannini, E., Schumacher, M., & Johansen, O. E. (2018). How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care, 41(2)